Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2019

View Archived Issues

Their antiviral work done, T cells go rogue

Clinical qualification of a novel P2X7-specific PET ligand in healthy volunteers

Phase III trial of tucidinostat/exemestane in advanced, HR-positive breast cancer

Sirona's SGLT2 inhibitor TFC-039 advancing through phase I trials

Protein provides protection against diabetic retinopathy

ADAMTS13 deficiency contributes to Alzheimer's disease cerebrovascular dysfunction

Phase II trial of axitinib plus pembrolizumab in patients with advanced sarcomas

Entera initiates phase II dose ranging study for oral PTH

University of Dundee and Bukwang Pharmaceutical partner to develop new treatment for PD

BST-236 demonstrates promising safety in patients with AML unfit for standard therapy

CARMIL2 variant linked to infantile onset of colitis and gastrointestinal eosinophilic disease

miRNAs and angiogenic factors as potential new biomarkers in CML

miR-451 is a potential therapeutic target for spinocerebellar ataxia type 2 treatment

FDA grants IND approval to novel PD-1/VEGF bispecific antibody for solid tumors

[177Lu]BL-01 as a radiotherapeutic agent for CXCR4-expressing lymphoma

Confo Therapeutics and DyNAbind establish GPCR drug discovery collaboration

European Commission approves Ultomiris for adults with PNH

FDA grants accelerated approval to Xpovio for relapsed refractory multiple myeloma

Synergys Biotherapeutics receives NCI funding for development of anti-HER2 antibody fusion candidate

Leo Pharma patents PDE4 inhibitors

GlaxoSmithKline identifies new IDO1 inhibitors for HIV infection

New PRMT5 inhibitors for cancer presented by Lupin

Gedeon Richter divulges vasopressin V1A receptor antagonists

VenatoRx Pharmaceuticals synthesizes HBV capsid assembly modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...